Welcome to CDC stacks | Carrageenan-Based Gel Retains Limited Anti-HIV-1 Activity 8–24 Hours After Vaginal Application by HIV-Infected Thai Women Enrolled in a Phase I Safety Trial - 47475 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Carrageenan-Based Gel Retains Limited Anti-HIV-1 Activity 8–24 Hours After Vaginal Application by HIV-Infected Thai Women Enrolled in a Phase I Safety Trial
Filetype[PDF-77.47 KB]


No Related Documents.
You May Also Like:
  1. Acceptability of Carraguard Vaginal Microbicide Gel among HIV-Infected Women in Chiang Rai, Thailand
    Personal Author:
    Whitehead, Sara J.; McLean, Catherine; Chaikummao, Supaporn; Braunstein, Sarah; Utaivoravit, Wat; van de Wijgert, Janneke H.; Mock, Philip A.; Siraprapasiri, Taweesap; Friedland, Barbara A.; Kilmarx, Peter H.; Markowitz, Lauri E.;
    Published:
    Sep 07 2011
    Source:
    PLoS One. 2011; 6(9).
    Description:
    Background : Few studies of microbicide acceptability among HIV-infected women have been done. We assessed Carraguard® vaginal gel acceptability among participants in a randomized, controlled, crossover safety trial in HIV-infected women in Thailand...
    File Type:
    Filetype[PDF - 159.91 KB]
  2. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women
    Personal Author:
    Carballo-Diéguez, Alex; Balán, Ivan C.; Brown, William; Giguere, Rebecca; Dolezal, Curtis; Leu, Cheng-Shiun; Marzinke, Mark A.; Hendrix, Craig W.; Piper, Jeanna M.; Richardson, Barbra A.; Grossman, Cynthia; Johnson, Sherri; Gomez, Kailazarid; Horn, Stephanie; Kunjara Na Ayudhya, Ratiya Pamela; Patterson, Karen; Jacobson, Cindy; Bekker, Linda-Gail; Chariyalertsak, Suwat; Chitwarakorn, Anupong; Gonzales, Pedro; Holtz, Timothy H.; Liu, Albert; Mayer, Kenneth H.; Zorrilla, Carmen; Lama, Javier; McGowan, Ian; Cranston, Ross D.;
    Published:
    Jul 27 2017
    Source:
    PLoS One. 12(7).
    Description:
    Trials to assess microbicide safety require strict adherence to prescribed regimens. If adherence is suboptimal, safety cannot be adequately assessed. MTN-017 was a phase 2, randomized sequence, open-label, expanded safety and acceptability crossover...
    File Type:
    Filetype[PDF - 3.03 MB]
  3. Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial: Importance of adherence for microbicide effectiveness
    Personal Author:
    Kashuba, Angela DM; Gengiah, Tanuja N; Werner, Lise; Yang, Kuo-Hsiung; White, Nicole R; Karim, Quarraisha Abdool; Abdool Karim, Salim S.;
    Published:
    Jul 1 2015
    Source:
    J Acquir Immune Defic Syndr. 69(3):264-269.
    Description:
    Objective : The CAPRISA 004 trial showed that coitally-dosed tenofovir 1% gel reduced HIV acquisition by 39% overall and 54% when used consistently. The objective of this analysis was to ascertain its pharmacokinetic-pharmacodynamic relationship to p...
    File Type:
    Filetype[PDF - 191.37 KB]
  4. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States
    Personal Author:
    Mofenson, Lynne M.
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.), Public Health Service Task Force.. National Center for HIV, STD, and TB Prevention (U.S.), Division of HIV/AIDS Prevention--Surveillance and Epidemiology.. United States, Public Health Service., Perinatal HIV Guidelines Working Group..
    Published:
    November 22, 2002
    Series:
    Morbidity and mortality weekly report. Recommendations and reports ; v. 51, no. RR-18
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 51, no. RR-18
    Description:
    "These recommendations update the February 4,2002, guidelines developed by the Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human immunodeficiency virus type 1 (HIV-1) transmission. This report provides healt...
    Status:
    superseded
    File Type:
    Filetype[PDF - 520.38 KB]
  5. Enrollment Characteristics and Risk Behaviors of Injection Drug Users Participating in the Bangkok Tenofovir Study, Thailand
    Personal Author:
    Martin, Michael.; Vanichseni, Suphak.; Suntharasamai, Pravan.; Sangkum, Udomsak.; Chuachoowong, Rutt.; Mock, Philip A.; Leethochawalit, Manoj.; Chiamwongpaet, Sithisat.; Kittimunkong, Somyot.; van Griensven, Frits.; McNicholl, Janet M.; Paxton, Lynn.; Choopanya, Kachit.;
    Corporate Author:
    for the Bangkok Tenofovir Study Group
    Published:
    Sep 28 2011
    Source:
    PLoS One. 2011; 6(9).
    Description:
    Background : The Bangkok Tenofovir Study was launched in 2005 to determine if pre-exposure prophylaxis with tenofovir will reduce the risk of HIV infection among injecting drug users (IDUs). We describe recruitment, screening, enrollment, and baselin...
    File Type:
    Filetype[PDF - 155.39 KB]